Reported Earnings • Aug 05
Second quarter 2026 earnings released: EPS: US$0.29 (vs US$0.42 in 2Q 2025) Second quarter 2026 results: EPS: US$0.29 (down from US$0.42 in 2Q 2025). Revenue: US$95.6m (flat on 2Q 2025). Net income: US$17.1m (down 36% from 2Q 2025). Profit margin: 18% (down from 28% in 2Q 2025). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Jul 17
Steel Partners Holdings Issues Letter to InMode Board Demanding Governance Reforms and Disclosure On July 16, 2026, Steel Partners Holdings L.P. issued a public letter to InMode Ltd.’s Board demanding the group led by CEO Moshe Mizrahy cure disclosure deficiencies, reschedule the Annual General Meeting to allow shareholders to review the full record and bring their own resolutions, and address persistent governance failures. Steel Partners questioned management’s actions around a going-private bid, transparency, and the independence of the Special Committee, and threatened to pursue remedies with regulators if demands are not met. Tillkännagivande • Jun 28
DOMA Perpetual Capital Sent a Letter to the Board of Directors of InMode On June 26, 2026, DOMA Perpetual Capital Management LLC announced that it has sent a letter to the Board of Directors of InMode Ltd., stating that it strongly opposes the proposed acquisition led by the Chief Executive Officer in partnership with a group of investors and plans to vote against the deal at the current offer of $16.20 per share, asserting that the offer materially undervalues the Company and its long-term potential and exploits depressed valuations created by years of CEO-led underperformance. In addition, DOMA Perpetual Capital stating its concerns about conflicts of interest, governance, fiduciary responsibilities, and the fairness of the proposed transaction, noting that the proposal follows a long period of operational underperformance under the current CEO and that the same CEO appears positioned to benefit from the transaction. Further, DOMA Perpetual Capital urged the Board to uphold its fiduciary duties by establishing a fully independent special committee with no ties to management, retaining independent financial and legal advisors, conducting a broad and transparent market check inviting public offers, and ensuring full and fair disclosure regarding the process, assumptions, and potential conflicts of interest. Tillkännagivande • Jun 26
M.N. Business Strategy, Ltd. proposed to acquire remaining shares InMode Ltd. (NasdaqGS:INMD). M.N. Business Strategy, Ltd. proposed to acquire remaining shares InMode Ltd. (NasdaqGS:INMD) on June 17, 2026. A cash consideration valued at $16.2 per share will be paid by M.N. Business Strategy, Ltd.
The Board of Directors of InMode Ltd. formed a special committee for the transaction. Tillkännagivande • Jun 19
InMode Ltd., Annual General Meeting, Jul 30, 2026 InMode Ltd., Annual General Meeting, Jul 30, 2026. Location: tavor building, shaar yokneam industrial park, yokneam Israel Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Nadav Kenneth was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 21
InMode Ltd. Announces the Appointment of Moshik Itzkovich as Chief Financial Officer, Effective May 20, 2026 InMode Ltd. announced the appointment of Moshik Itzkovich as Chief Financial Officer, effective May 20, 2026. Moshik has held senior finance roles at InMode and was previously Senior Vice President of Finance. He replaces Yair Malca, who stepped down earlier this month and will serve as a consultant at least through the Company's Annual General Meeting to ensure a smooth transition. Tillkännagivande • May 20
InMode Ltd. Announces the Appointment of Shlomo Nass as Chairman of the Board of Directors , Effective May 20, 2026 InMode Ltd. announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors, effective May 20, 2026. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accounting, governance, and audit oversight, with extensive experience advising public and private companies on complex regulatory and financial matters. Tillkännagivande • Apr 14
InMode Ltd. to Report Q1, 2026 Results on May 06, 2026 InMode Ltd. announced that they will report Q1, 2026 results Pre-Market on May 06, 2026 Tillkännagivande • Jan 29
Steel Partners Holdings L.P. proposed to acquire an additional 51% stake in InMode Ltd. (NasdaqGS:INMD) for approximately $580 million. Steel Partners Holdings L.P. proposed to acquire an additional 51% stake in InMode Ltd. (NasdaqGS:INMD) for approximately $580 million on January 28, 2026. A cash consideration valued at $18 per share will be paid by Steel Partners Holdings L.P. As part of consideration, an undisclosed value is paid towards common equity of InMode Ltd. Upon completion, Steel Partners Holdings L.P. will own 52.30% stake in InMode Ltd. The proposal would be fully funded from cash on hand and borrowing capacity under existing credit facility, with no financing contingency. Tillkännagivande • Nov 04
InMode Ltd. Appoints Michael Dennison as President of North America InMode Ltd. has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market share, and strengthening the company's distribution network across North America. Before joining InMode, Dennison held multiple leadership positions at Cynosure, where he consistently exceeded sales targets and built high-performing teams that drove significant revenue growth. Tillkännagivande • Sep 19
Court Partially Grants Motion to Dismiss in Securities Class Action Against Inmode Ltd InMode Ltd. announced that As previously disclosed, on February 14, 2024, a purported shareholder of the Company filed a putative shareholder class action (the “Securities Class Action”) in the United States District Court for the Central District of California (the “Court”), captioned Cement Masons and Plasterers Local No. 502 Pension Fund v. InMode Ltd. et al., Case No. 2:24-cv-01219, against the Company and certain of its officers and directors. The complaint alleges claims under Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements related to the Company’s business, operations, sales practices and financial outlook. The lawsuit seeks unspecified damages and other relief. On April 11, 2025, the Company filed a motion to dismiss the amended complaint, asserting, among other arguments, that the allegations in the amended complaint are legally insufficient and fail to support the lead plaintiffs’ claims. On June 20, 2025, the lead plaintiffs filed an opposition to the Company’s motion to dismiss, and on July 21, 2025, the Company filed a reply in support its motion to dismiss. On September 12, 2025, the Court entered an order that, among other things, dismissed with leave to amend 19 of the 24 statements that were the subject of the lead plaintiffs’ amended complaint. As of the date of this filing, the Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in the Securities Class Action, and an estimated liability has not been recorded in the Company’s financial statements. The defendants intend to continue to deny the allegations of wrongdoing and vigorously defend against the claims in the Securities Class Action. Tillkännagivande • Sep 10
DOMA Perpetual Sends Letter to InMode Ltd On September 9, 2025, DOMA Perpetual Capital Management LLC announced that it has sent a letter to the Board of InMode Ltd. urging them to approve a 10% buyback of shares in Q4 2025 and another 10% buyback in Q1 2026. DOMA Perpetual added that the letter highlighted concerns regarding management's chaotic leadership and the need for the Board to fulfill its fiduciary duty to act in the best interests of shareholders. DOMA Perpetual stated that emphasized that the Company holds a significant amount of cash relative to its market capitalization and that returning capital to shareholders through buybacks is a prudent strategy and the Board was reminded of its legal obligations and the potential consequences of failing to act in shareholders' interests. Tillkännagivande • May 06
InMode Ltd. Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges InMode Ltd. reported that the US District Court for the Central District of California granted InMode's motion for default judgment against the DHGate sellers and awarded InMode a permanent injunction and damages for the defendants' sales and promotion of counterfeit goods. The Court's decision aims to protect safety and uphold InMode's trademark rights. The injunction includeszing the assets and halting the listings of the sellers involved in the counterfeit trade. The ruling focuses InMode on all claims (trademark infringement, false designation of origin, and California unfair competition), and (1) granted a permanent injunction enjoining the sellers from infringing upon the MORPHEUS and INMode trademarks, and (2) awarded InMode damages per defendant. InMode has established a Verified Provider Program for Morpheus8, allowing certified clinics to showcase their authenticity and confirm they use genuine Morpheus8 technology. This initiative helps patients identify safe, authorized providers committed to delivering trusted InMode results. Tillkännagivande • Apr 14
InMode Ltd. to Report Q1, 2025 Results on Apr 28, 2025 InMode Ltd. announced that they will report Q1, 2025 results Pre-Market on Apr 28, 2025 Tillkännagivande • Apr 04
InMode Ltd., Annual General Meeting, May 15, 2025 InMode Ltd., Annual General Meeting, May 15, 2025. Location: tavor building, shaar yokneam industrial park, yokneam, Israel Tillkännagivande • Feb 04
InMode Ltd. Provides Revenue Guidance for the Full Year of 2025 Ending December 31, 2025 InMode Ltd. provided revenue guidance for the full year of 2025 ending December 31, 2025. For the period, the company expects revenues between $395 to $405 million. Tillkännagivande • Jan 08
InMode Ltd. to Report Q4, 2024 Results on Feb 06, 2025 InMode Ltd. announced that they will report Q4, 2024 results Pre-Market on Feb 06, 2025 Board Change • Dec 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Chairman Michael Anghel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: US$0.66 (vs US$0.56 in 3Q 2023) Third quarter 2024 results: EPS: US$0.66 (up from US$0.56 in 3Q 2023). Revenue: US$130.2m (up 5.8% from 3Q 2023). Net income: US$51.0m (up 9.6% from 3Q 2023). Profit margin: 39% (up from 38% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Oct 02
InMode Ltd. Announces Executive Departures InMode Ltd. announced departure of Shakil Lakhani, President of North America, effective September 30, 2024. His departure follows that of Dr. Spero Theodorou, Chief Medical Officer. These changes come as part of InMode's ongoing effort to establish an optimal company structure that aligns with its global expansion and penetration into new business verticals. Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: US$0.28 (vs US$0.67 in 2Q 2023) Second quarter 2024 results: EPS: US$0.28 (down from US$0.67 in 2Q 2023). Revenue: US$86.4m (down 37% from 2Q 2023). Net income: US$23.8m (down 57% from 2Q 2023). Profit margin: 28% (down from 41% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Aug 01
InMode Ltd. Revises Earnings Guidance for the Full Year Ending December 31, 2024 InMode Ltd. revised earnings guidance for the full year ending December 31, 2024. For the year, the company expects revenue to be $430 million to $440 million compared to prior guidance of $485 million to $495 million. Tillkännagivande • Jul 31
Inmode Introduces Igniterf the Complete Minimally Invasive Soft Tissue Contraction Platform InMode Ltd. announce the introduction of IgniteRF, a ground-breaking minimally invasive workstation inclusive of nine technologies which offer soft tissue contraction across multiple tissue depths. The IgniteRF platform, alongside the BodyTite, FaceTite, Morpheus8, and now QuantumRF family of products offers a comprehensive suite of radiofrequency solutions for various aesthetic and surgical needs. QuantumRF is a new, advanced minimally invasive technology which deploys fractionated radiofrequency to maximal depths. The two lightweight and versatile cannulas, QuantumRF 10 for small, more delicate treatment zones and QuantumRF 25 for larger treatment zones enable physicians to deliver unprecedented results without invasive surgery. Radiofrequency (RF) technology has emerged as the gold standard in skin contraction within the aesthetics industry, due to its effectiveness, safety, and minimally or non-invasive nature. RF treatments heat the deeper layers of the skin, stimulating collagen production and promoting tissue remodeling. This process results in contracted, firmer skin and a more youthful appearance. One of the primary reasons RF is favored in aesthetics is its ability to deliver consistent and noticeable results with minimal discomfort and downtime. Unlike more surgical procedures, RF treatments do not require incisions or extensive surgery and recovery periods. Tillkännagivande • Jul 18
InMode Ltd. Announces an Additional FDA 510(K) Clearance for the Morpheus8 Technology InMode Ltd. announced an additional FDA 510(k) clearance for the Morpheus8 technology. Morpheus8 is the first and only fractional radiofrequency (FRF) microneedling technology cleared for contraction of soft tissue. The U.S. Food and Drug Administration (FDA) has cleared the use of the Morpheus8 Applicators for the delivery of fractional radiofrequency use in dermatologic skin procedures where coagulation/contraction of soft tissue or hemostasis is needed. This FDA action expands Morpheus8's existing FDA clearance, emphasizing the versatility of the technology for physicians and patients. Coinciding with this clearance is the launch of the new IgniteRF and OptimasMAX platforms, which include the Morpheus8 family of handpieces. The modular portfolio of tips, including Prime 12 pin, Morpheus8 24 pin, Resurfacing 24 pin, and Morpheus8 40 pin, makes this technology a versatile solution delivering exceptional patient results. The IgniteRF and Optimas MAX platforms support 14 technologies, including minimally invasive radiofrequency assisted soft tissue coagulation and contraction, non-invasive thermal radiofrequency, intense pulsed light skin treatments, and multi-wavelength hair reduction. Since inception, Morpheus8 has gained widespread global brand awareness, with more than 2.5 million procedures performed worldwide, and an average of 8.2 treatments performed every minute. The Morpheus8 brand has become so popular that consumers and celebrities request it by name. It is a trusted procedure known for delivering both natural and striking results. Tillkännagivande • May 03
InMode Ltd. Revises Earnings Guidance for the Full Year Ending December 31, 2024 InMode Ltd. revised earnings guidance for the full year ending December 31, 2024. For the year, the company expects revenue to be $485 million to $495 million compared to previous guidance of $495 million to $505 million. Reported Earnings • May 02
First quarter 2024 earnings released: EPS: US$0.28 (vs US$0.49 in 1Q 2023) First quarter 2024 results: EPS: US$0.28 (down from US$0.49 in 1Q 2023). Revenue: US$80.3m (down 24% from 1Q 2023). Net income: US$23.7m (down 42% from 1Q 2023). Profit margin: 30% (down from 38% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Apr 10
InMode Ltd. to Report Q1, 2024 Results on May 02, 2024 InMode Ltd. announced that they will report Q1, 2024 results Pre-Market on May 02, 2024 Tillkännagivande • Apr 09
Inmode Ltd. Provides Revenue Guidance for the First Quarter of 2024 InMode Ltd. provided revenue guidance for the first quarter of 2024. For the year, the company expects Revenue to be in the range of $80.0 million to $80.1 million. Tillkännagivande • Apr 05
Pomerantz Law Firm Announces the Filing of a Class Action Against Inmode Ltd Pomerantz LLP announces that a class action lawsuit has been filed against InMode Ltd. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether InMode and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until April 15, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired InMode securities during the Class Period. On February 17, 2023, an investigative publication revealed that InMode had threatened certain customers with legal action over complaints made about the Company's devices and sales tactics. The customers also stated that InMode offered to replace defective products on the condition of signing confidentiality agreements with non-disparagement clauses. On this news, InMode's stock price fell $1.21 per share, or 3.27%, to close at $35.81 per share on February 21, 2023. Then, on October 12, 2023, InMode lowered its full-year revenue guidance, citing higher interest rates, tighter leasing approval standards, and bottlenecks in loan processing. Later that same day, an investigative publication announced a forthcoming report on InMode, relating to the Company's statements to investors about pricing flexibility of products and margin consistency. After the close of trading, the publication released that story, revealing that the Company had routinely and significantly discounted the prices of its devices.On this news, InMode's stock price fell $7.24 per share, or 25.87%, over the following two trading sessions, to close at $20.75 per share on October 13, 2024. Tillkännagivande • Apr 02
Pomerantz Law Firm Announces the Filing of a Class Action Against InMode Ltd Pomerantz LLP announced that a class action lawsuit has been filed against InMode Ltd. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether InMode and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On February 17, 2023, an investigative publication revealed that InMode had threatened certain customers with legal action over complaints made about the Company’s devices and sales tactics. The customers also stated that InMode offered to replace defective products on the condition of signing confidentiality agreements with non-disparagement clauses. On this news, InMode’s stock price fell $1.21 per share, or 3.27%, to close at $35.81 per share on February 21, 2023. Then, on October 12, 2023, InMode lowered its full-year revenue guidance, citing higher interest rates, tighter leasing approval standards, and bottlenecks in loan processing. Later that same day, an investigative publication announced a forthcoming report on InMode, relating to the Company’s statements to investors about pricing flexibility of products and margin consistency. After the close of trading, the publication released that story, revealing that the Company had routinely and significantly discounted the prices of its devices. On this news, InMode’s stock price fell $7.24 per share, or 25.87%, over the following two trading sessions, to close at $20.75 per share on October 13, 2024. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €18.56, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 45% over the past year. Tillkännagivande • Feb 16
Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against InMode Ltd Bragar Eagel & Squire, P.C. announced that a class action lawsuit has been filed against InMode Ltd. in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired InMode common stock between June 4, 2021 and October 12, 2023, both dates inclusive (Class Period). Investors have until April 15, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and omissions concerning two topics that are of critical importance to investors: (1) the price at which InMode sells its devices, which reflects the demand for those products; and (2) InMode’s compliance with U.S. Food and Drug Administration (“FDA”) regulations, including the FDA’s prohibition on off-label marketing of devices and the FDA’s requirements for the reporting of injuries. Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount. InMode also assured investors that it had “obtained [FDA] clearance for the current treatments for which offer products” and that “no third-party claims have been brought against to date.” As a result of these misrepresentations, the price of InMode common stock traded at artificially inflated prices throughout the Class Period. According to the complaint, in reality, throughout the Class Period, InMode routinely discounted the prices of its devices and violated FDA regulations by promoting the off-label use of its devices, and by failing to properly report injuries caused by its devices. The complaint further alleges that the truth began to emerge just before the market closed on February 17, 2023, when an investigative publication revealed that InMode threatened some customers with legal action over complaints made about the Company’s devices and sales tactics. The customers also stated that InMode offered to replace defective products on the condition of signing confidentiality agreements with non-disparagement clauses. However, despite these disclosures, InMode continued to misrepresent the pricing of, and demand for, its products. Then, on October 12, 2023, before the market opened, InMode lowered its full-year revenue guidance, which the Company blamed on higher interest rates, tighter leasing approval standards, and bottlenecks in loan processing. Later that same day, an investigative publication announced a forthcoming report on InMode, relating to the Company’s statements to investors about pricing flexibility of products and margin consistency. After the close of trading, the publication released a story revealing that InMode significantly discounted the prices of its devices on a routine basis throughout the Class Period. As a result of these disclosures, the price of InMode common stock declined precipitously. New Risk • Feb 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (82% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Tillkännagivande • Feb 14
InMode Ltd., Annual General Meeting, Apr 01, 2024 InMode Ltd., Annual General Meeting, Apr 01, 2024, at 17:00 Israel Standard Time. Location: Tavor Building, Sha'ar Yokneam Industrial Park, Yokne'am Israel Agenda: To re-elect Dr. Michael Anghel who is an incumbent director and to elect Mr. Nadav Kenneth as a new director, replacing Mr. Bruce Mann who is retiring to the Company's board of directors, both to serve as a Class II directors of the Company, and to hold office until the close of business of the annual general meeting of shareholders to be held in 2027 and until such individual's successor is duly elected and qualified, or until such individual's earlier resignation or retirement; and to consider other matters. Reported Earnings • Feb 13
Full year 2023 earnings released: EPS: US$2.37 (vs US$1.96 in FY 2022) Full year 2023 results: EPS: US$2.37 (up from US$1.96 in FY 2022). Revenue: US$492.0m (up 8.3% from FY 2022). Net income: US$197.9m (up 23% from FY 2022). Profit margin: 40% (up from 36% in FY 2022). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Jan 17
InMode Ltd. to Report Q4, 2023 Results on Feb 13, 2024 InMode Ltd. announced that they will report Q4, 2023 results Pre-Market on Feb 13, 2024 Tillkännagivande • Jan 16
InMode Ltd. Provides Revenue Guidance for the Fourth Quarter, Full Year of 2023 and for the Full Year of 2024 InMode Ltd. provided revenue guidance for the fourth quarter, full year of 2023 and for the full year of 2024. Revenue for the fourth quarter of 2023 to be in the range of $126.0 million to $126.5 million.Revenue for the full year of 2023 to be in the range of $491.3 million to $491.8 million.Full year 2024 revenue to be in the range of $495 million to $505 million. Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €19.09, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 45% over the past year. Tillkännagivande • Dec 06
InMode Ltd. Revises Earnings Guidance for the Full Year 2023 InMode Ltd. revised earnings guidance for the full year 2023. For the year, the company expects Revenue to be in the range of $485 million to $495 million, as compared to the prior estimated range of $500 million to $510 million. Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: US$0.56 (vs US$0.59 in 3Q 2022) Third quarter 2023 results: EPS: US$0.56 (down from US$0.59 in 3Q 2022). Revenue: US$123.1m (up 1.6% from 3Q 2022). Net income: US$46.5m (down 4.7% from 3Q 2022). Profit margin: 38% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to €21.04, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 32% over the past year. New Risk • Jul 28
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 28
Second quarter 2023 earnings released: EPS: US$0.67 (vs US$0.54 in 2Q 2022) Second quarter 2023 results: EPS: US$0.67 (up from US$0.54 in 2Q 2022). Revenue: US$136.1m (up 20% from 2Q 2022). Net income: US$55.7m (up 27% from 2Q 2022). Profit margin: 41% (up from 39% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Jul 26
InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc. InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc. on July 25, 2023. All of Viveve's worldwide patents will be transferred and registered under InMode Ltd.
InMode Ltd. (NasdaqGS:INMD) completed the acquisition of Intellectual Property Assets of Viveve Medical Inc. on July 25, 2023. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €40.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €58.74 per share. Reported Earnings • May 04
First quarter 2023 earnings released: EPS: US$0.49 (vs US$0.37 in 1Q 2022) First quarter 2023 results: EPS: US$0.49 (up from US$0.37 in 1Q 2022). Revenue: US$106.1m (up 24% from 1Q 2022). Net income: US$40.5m (up 31% from 1Q 2022). Profit margin: 38% (up from 36% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €34.54, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total returns to shareholders of 16% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €55.19 per share. Tillkännagivande • Feb 15
InMode Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2023 InMode Ltd. provided earnings guidance for the full year ending December 31, 2023. For the period, the company expected revenue between $525 million and $530 million. Reported Earnings • Feb 15
Full year 2022 earnings released: EPS: US$1.96 (vs US$2.03 in FY 2021) Full year 2022 results: EPS: US$1.96 (down from US$2.03 in FY 2021). Revenue: US$454.3m (up 27% from FY 2021). Net income: US$161.5m (down 2.1% from FY 2021). Profit margin: 36% (down from 46% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Nov 26
InMode Ltd. Receives Health Canada Certification of Forma-I for Dry Eye Disease Due to Meibomian Gland Dysfunction InMode Ltd. announced the Health Canada license of the Forma-I to address the symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). Forma-I is intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation. MGD is a major cause of ocular discomfort, and 86% of dry eye patients demonstrate signs of MGD. The North American dry eye market size reached $2.4 billion in 2021. This critical Canadian certification opens opportunities for InMode to provide a non-drug alternative for millions of MGD and dry eye sufferers. InMode's Forma-I is an innovative thermal technology that delivers targeted bipolar radiofrequency energy to small, delicate ocular areas. Treatments are quick and easy and performed safely in-office. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Michael Anghel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: US$0.59 (vs US$0.54 in 3Q 2021) Third quarter 2022 results: EPS: US$0.59 (up from US$0.54 in 3Q 2021). Revenue: US$121.2m (up 29% from 3Q 2021). Net income: US$48.8m (up 9.1% from 3Q 2021). Profit margin: 40% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment improved over the past week After last week's 16% share price gain to €37.32, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €74.38 per share. Reported Earnings • Jul 29
Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.50 in 2Q 2021) Second quarter 2022 results: EPS: US$0.54 (up from US$0.50 in 2Q 2021). Revenue: US$113.5m (up 30% from 2Q 2021). Net income: US$44.0m (up 7.6% from 2Q 2021). Profit margin: 39% (down from 47% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 7.0% growth forecast for the industry in Germany. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 18% share price gain to €26.39, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Tillkännagivande • Jun 16
InMode Ltd. Receives Health Canada Certification of EmpowerRF Women's Wellness Technology InMode Ltd. announced the EmpowerRF Women's Wellness launch in Canada. InMode has recently received Health Canada certification to improve urinary incontinence symptoms (SUI). This adds to previous licences for improving the symptoms of Genitourinary Syndrome of Menopause (GSM), chronic pelvic pain, and blood circulation. InMode's multi-functional platform is the most advanced and comprehensive feminine wellness solution available, leveraging synergistic complementary modalities, including intravaginal electrical muscle stimulation (EMS), fractional electrocoagulation of mucosa, and bipolar radiofrequency (RF). Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €20.50, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 16% share price gain to €24.64, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 30x in the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €20.60, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Reported Earnings • May 04
First quarter 2022 earnings released: EPS: US$0.37 (vs US$0.34 in 1Q 2021) First quarter 2022 results: EPS: US$0.37 (up from US$0.34 in 1Q 2021). Revenue: US$85.9m (up 31% from 1Q 2021). Net income: US$31.0m (up 16% from 1Q 2021). Profit margin: 36% (down from 41% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 16%, compared to a 11% growth forecast for the industry in Germany. Board Change • Apr 27
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & CEO Moshe Mizrahy is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 18
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & CEO Moshe Mizrahy is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. 
